CSPC Pharmaceutical Group Limited
HKEX:1093.HK
5.47 (HKD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 34,752.307 | 35,975.851 | 33,585.457 | 28,027.389 | 25,063.174 | 18,468.728 | 12,920.599 | 11,075.282 | 9,540.875 | 8,760.122 | 7,774.297 | 3,338.689 | 5,972.422 | 6,625.558 | 6,190.968 | 6,013.841 | 4,670.921 | 3,548.31 | 3,322.736 | 2,610.916 | 2,642.56 |
| Cost of Revenue
| 10,247.114 | 10,094.353 | 8,113.21 | 7,030.817 | 7,021.45 | 6,249.739 | 5,111.042 | 5,426.353 | 5,169.018 | 5,411.745 | 5,326.102 | 1,885.041 | 4,773.372 | 4,687.951 | 4,194.732 | 4,005.116 | 3,231.61 | 2,933.329 | 2,600.78 | 1,938.815 | 1,656.344 |
| Gross Profit
| 24,505.194 | 25,881.499 | 25,472.247 | 20,996.572 | 18,041.724 | 12,218.989 | 7,809.557 | 5,648.929 | 4,371.858 | 3,348.376 | 2,448.195 | 1,453.648 | 1,199.05 | 1,937.608 | 1,996.237 | 2,008.725 | 1,439.31 | 614.981 | 721.956 | 672.101 | 986.216 |
| Gross Profit Ratio
| 0.705 | 0.719 | 0.758 | 0.749 | 0.72 | 0.662 | 0.604 | 0.51 | 0.458 | 0.382 | 0.315 | 0.435 | 0.201 | 0.292 | 0.322 | 0.334 | 0.308 | 0.173 | 0.217 | 0.257 | 0.373 |
| Reseach & Development Expenses
| 5,337.555 | 4,635.833 | 4,136.995 | 3,247.291 | 2,268.316 | 1,390.466 | 815.258 | 403.14 | 324.505 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 1,189.648 | 1,172.842 | 1,009.824 | 945.713 | 0 | 684.965 | 0 | 495.78 | 447.899 | 441.159 | 484.7 | 189.513 | 487.782 | 533.632 | 406.347 | 453.013 | 441.493 | 308.926 | 305.235 | 245.046 | 213.451 |
| Selling & Marketing Expenses
| 9,140.652 | 10,337.423 | 10,443.422 | 9,377.62 | 0 | 6,436.102 | 0 | 2,496.528 | 1,898.305 | 1,429.783 | 1,016.406 | 609.77 | 422.246 | 443.861 | 517.565 | 414.53 | 355.236 | 0 | 0 | 140.05 | 100.789 |
| SG&A
| 11,435.306 | 13,352.638 | 13,808.483 | 11,643.096 | 10,727.521 | 7,121.067 | 4,225.371 | 2,992.308 | 2,346.203 | 1,870.942 | 1,501.106 | 799.283 | 910.028 | 977.493 | 923.912 | 867.543 | 796.729 | 308.926 | 305.235 | 385.095 | 314.24 |
| Other Expenses
| 3.652 | 814.849 | 545.694 | 0 | 0 | 181.192 | 0 | 284.265 | 211.51 | 138.542 | 25.046 | 39.538 | -16.193 | 90.99 | -45.788 | -10.362 | -116.043 | -303.631 | -251.341 | -3.973 | 12.74 |
| Operating Expenses
| 16,769.209 | 17,988.471 | 17,945.478 | 14,890.387 | 12,995.837 | 8,233.71 | 4,900.271 | 3,276.572 | 2,557.714 | 2,009.484 | 1,526.152 | 838.821 | 893.835 | 1,068.483 | 965.615 | 936.194 | 866.822 | 308.926 | 305.235 | 381.123 | 326.98 |
| Operating Income
| 7,735.985 | 7,893.028 | 7,526.769 | 6,106.186 | 5,045.886 | 4,053.616 | 2,887.663 | 2,385.951 | 1,803.74 | 1,327.369 | 1,018.651 | 1,895.667 | 299.766 | 856.861 | 980.394 | 1,066.212 | 602.143 | 1.604 | 155.091 | 294.436 | 664.383 |
| Operating Income Ratio
| 0.223 | 0.219 | 0.224 | 0.218 | 0.201 | 0.219 | 0.223 | 0.215 | 0.189 | 0.152 | 0.131 | 0.568 | 0.05 | 0.129 | 0.158 | 0.177 | 0.129 | 0 | 0.047 | 0.113 | 0.251 |
| Total Other Income Expenses Net
| 489.143 | 942.121 | 698.378 | 1,060.159 | 133.566 | -100.052 | 7.957 | -26.266 | -35.153 | -30.765 | -43.749 | -43.059 | -45.345 | -34.657 | 10.825 | -90.601 | -2.683 | 0 | 0 | -28.976 | -24.074 |
| Income Before Tax
| 8,225.128 | 8,835.149 | 8,225.147 | 7,166.344 | 5,179.453 | 3,953.564 | 2,895.62 | 2,359.685 | 1,768.587 | 1,296.604 | 974.902 | 1,852.607 | 254.421 | 822.205 | 991.219 | 975.61 | 489.334 | 1.604 | 155.091 | 265.461 | 640.309 |
| Income Before Tax Ratio
| 0.237 | 0.246 | 0.245 | 0.256 | 0.207 | 0.214 | 0.224 | 0.213 | 0.185 | 0.148 | 0.125 | 0.555 | 0.043 | 0.124 | 0.16 | 0.162 | 0.105 | 0 | 0.047 | 0.102 | 0.242 |
| Income Tax Expense
| 1,454.928 | 1,570.131 | 1,396.806 | 1,305.746 | 1,012.372 | 766.709 | 572.596 | 467.496 | 362.102 | 269.601 | 201.856 | 106.265 | 51.726 | 161.891 | 125.707 | 141.746 | 42.689 | -13.8 | -7.6 | 4.021 | 101.268 |
| Net Income
| 5,873.325 | 6,091.39 | 5,605.185 | 5,159.655 | 4,211.486 | 3,210.006 | 2,315.068 | 1,881.107 | 1,394.464 | 1,014.301 | 760.114 | 1,741.017 | 188.705 | 640.608 | 854.686 | 828.167 | 446.645 | 15.404 | 162.691 | 260.628 | 536.075 |
| Net Income Ratio
| 0.169 | 0.169 | 0.167 | 0.184 | 0.168 | 0.174 | 0.179 | 0.17 | 0.146 | 0.116 | 0.098 | 0.521 | 0.032 | 0.097 | 0.138 | 0.138 | 0.096 | 0.004 | 0.049 | 0.1 | 0.203 |
| EPS
| 0.55 | 0.59 | 0.57 | 0.49 | 0.35 | 0.27 | 0.2 | 0.16 | 0.12 | 0.089 | 0.071 | 0.62 | 0.13 | 0.22 | 0.29 | 0.28 | 0.15 | 0.005 | 0.055 | 0.088 | 0.089 |
| EPS Diluted
| 0.55 | 0.59 | 0.57 | 0.49 | 0.35 | 0.27 | 0.2 | 0.16 | 0.12 | 0.089 | 0.067 | 0.22 | 0.035 | 0.22 | 0.29 | 0.28 | 0.15 | 0.005 | 0.055 | 0.088 | 0.089 |
| EBITDA
| 8,967.157 | 9,109.181 | 8,567.772 | 7,013.105 | 5,830.097 | 4,708.869 | 2,887.663 | 2,912.204 | 2,310.573 | 1,815.319 | 1,531.475 | 2,049.714 | 782.594 | 1,346.168 | 1,422.547 | 1,481.137 | 996.533 | 334.795 | 427.859 | 490.282 | 820.011 |
| EBITDA Ratio
| 0.258 | 0.253 | 0.255 | 0.25 | 0.233 | 0.255 | 0.223 | 0.263 | 0.242 | 0.207 | 0.197 | 0.614 | 0.131 | 0.203 | 0.23 | 0.246 | 0.213 | 0.094 | 0.129 | 0.188 | 0.31 |